Expression changes of serotonin receptor gene subtype 5HT3a in peripheral blood mononuclear cells from schizophrenic patients treated with haloperidol and olanzapin

Iranian Journal of Allergy, Asthma and Immunology

Volumn 8, Issue 3, 2009, Pages 135-139

  Shariati, Gholam Reza ^a,b   Ahangari, Ghasem ^a   Hossein nezhad, Arash ^a,c   Asadi, Seyed Mohammad ^d   Pooyafard, Farzaneh ^d   Ahmadkhaniha, Hamid Reza ^e  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^b Jundishahpour Medical Science University   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

5HT3a; Haloperidol; Olanzapin; Schizophrenia; Serotonin receptor

Indexed keywords

BETA ACTIN; COMPLEMENTARY DNA; HALOPERIDOL; MESSENGER RNA; OLANZAPINE; SEROTONIN 3A RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HALOPERIDOL; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, SEROTONIN, 5-HT3; SCHIZOPHRENIA;

EID: 76749142066     PISSN: 17351502     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Thompson AJ, Sullivan NL, Lummis SC. Characterization of 5-HT3 Receptor Mutations Identified in Schizophrenic Patients.J Mol Neurosci 2006; 30(3):273-81.
2. Gaddum JH, Hameed KA. Drugs which antagonize 5-hydroxytryptamine. Br J Pharmacol Chemother 1954; 9(2):240-8.
3. Wooley DW, Shaw E. A biochemical and Pharmacological suggestion about certain mental disorders. Porc Natl acad Sci USA 1954; 40(4):228-31.
4. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 2005; 55(4):242-51.
5. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989; 99(Suppl):S18-27.
6. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991; 254(5030):432-7.
7. Brian C Lund, Paul J Perry. Olanzapine: an atypical antipsychotic for schizophrenia. Expert Opinion on Pharmacotherapy 2000; 1(2):305-23
8. Bouman WP, Pinner G. Use of atypical antipsychotic drugs in old age psychiatry. Advan Psychiatr Treat 2002; 8:49-58.
9. Weiss EL, Longhurst JG, Bowers MB Jr, Mazure CM. Olanzapine for treatment-refractory psychosis in patients responsive to clozapine. J Clin Psychopharmacol 1999; 19(4):378-80.
10. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000; 157(5):683-94.
11. Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, Michie PT, et al. Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 2006; 82(2-3):175-83.
12. Chertkow Y, Weinreb O, Youdim MB, Silver H. Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(7):1356-62.
13. Hossein-nezhad A, Ahangari G, Larijani B. Evaluating of VDR gene variation and its interaction with Immune Regulatory Molecules in Osteoporosis. Iran J Publ Health 2009; 38(2):27-36.
14. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press, 2001.
15. NCBI-National center for biotechnology information, NCBI Blast home page. http:// www. ncbi.nlm.nih.gov/Blast/ last access on 25-1-2009
16. Grimaldi B, Fillion G. 5-HT-moduline controls serotonergic activity: implication in neuroimmune reciprocal regulation mechanisms. Prog Neurobiol 2000; 60(1):1-12.
17. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006; 141B (3):261-8.
18. Silver H, Nassar A, Aharon N, Kaplan A. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. Int Clin Psychopharmacol 2003; 18(2):87-92.
19. Padin JF, Rodriguez MA, Dominguez E, Dopeso-Reyes IG, Buceta M, Cano E, et al. Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells. Neuropharmacology 2006; 51(4):923-32.
20. Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA. Olanzapine: a basic science update. Br J Psychiatry Suppl 1999; (37):36-40.
21. Huang XF, Han M, Huang X, Zavitsanou K, Deng C. Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain. Behav Brain Res 2006; 171(2):355-62.
22. Muma NA, Singh RK, Vercillo MS, D'Souza DN, Zemaitaitis B, Garcia F, et al. Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex. Neuropharmacology 2007; 53(4):552-62.
23. Damask SP, Bovenkerk KA, de la Pena G, Hoversten KM, Peters DB, Valentine AM, et al. Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex. Brain Res Mol Brain Res 1996; 41(1-2):241-9.